CrowdStrike Bags 2 Price Target Raise Amid Cybersecurity Breach Concerns
Piper Sandler analyst Rob Owens reiterated an Overweight rating on CrowdStrike Holdings Inc’s (NASDAQ:CRWD) and raised the price target to $280 from…
How Ferrari’s EV Future Could Lead To $350 Per Share: Analyst
Morgan Stanley analyst Adam Jonas released a note on Wednesday detailing how electric vehicles could drive Ferrari N.V. (NYSE: RACE) shares to $350.
The Ferrari Analyst: Morgan Stanley maintained an Overweight rating on Ferrari with a $265 price target.
Why This Bed Bath & Beyond Analyst Is Raising Their Price Target By 60%
Bed Bath & Beyond Inc. (NASDAQ: BBBY) reported last week with strong quarterly revenues, although earnings missed expectations.
Should Investors Buy Amazon Stock Following Its Streaming Deal With Comcast?
CNBC's "Squawk Box" host Melissa Lee reported Friday that Amazon.com Inc (NASDAQ: AMZN) signed a new streaming deal with Comcast Corp (NASDAQ: CMCSA).
Costco Shares Gain Premarket After June Sales Jump 16.9%, Morgan Stanley Raises Price Target
Costco Wholesale Corporation (NASDAQ:COST) reported net sales of $18.92 billion for the retail month of June, a 16.9% growth year-on-year. The…
6 Top Precious Metal Stock Picks
On Thursday, Bank of America updated its precious metal price outlook and named its top precious metal stock picks for investors to buy heading into the second half of 2021.
Why JPMorgan Is Raising Tesla Delivery Estimates, EPS Estimates, Price Target
JPMorgan analysts increased several estimates for Tesla, Inc. (NASDAQ: TSLA) Wednesday following the automaker’s second-quarter vehicle delivery update.
Arrowhead’s Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.
Takeaways On Unity Biotech’s Clinical Data From A Bull Analyst
Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX).
The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target.
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: ABUS).
The Arbutus Analyst: Ed Arce raffirmed a Buy rating on shares of Arbutus Biopharma Corp. with a $10 price target.